Akums Drugs & Pharmaceuticals Ltd Share Price

Akums Drugs and Pharmaceuticals Ltd., founded in 2004 and headquartered in Delhi, India, has rapidly established itself as a prominent player in the pharmaceutical industry. The company has carved out a niche as a leading Contract Development and Manufacturing Organization (CDMO). It offers a comprehensive range of pharmaceutical products and services.

Akums’ main promoter is the Akums Master Trust, which holds 40.79% of its equity. The company’s Managing Directors, Mr. Sanjeev Jain and Mr. Sandeep Jain, own 17.23% and 17.24% stakes, respectively. Under their leadership, Akums has experienced significant growth. It has also built a strong reputation for quality and innovation. Apart from them, there are other managerial promoters who have contributed to the company's success. They are

• Sanjay Sinha
  
• Matangi Gowrishankar
  
• Nand Lal Kalra
  
• Sunil Kumar Thakur
  
• Kewal Kundanlal Handa
  
• Satwinder Singh
  

Akum’s diverse portfolio allows it to cater to a wide array of healthcare needs and market demands. Its expertise spans various dosage forms, including oral solids, injectables, cosmetics and nutraceuticals. The company’s registered office is located at LSC Saraswati Vihar, Delhi. Meanwhile, its registrars are based in Vikhroli, Mumbai.

Akums’ success is underpinned by its commitment to providing customised solutions that meet global standards. The company is renowned for its high-quality, safe, and effective formulations. Its manufacturing facilities and expertise have positioned it as a preferred partner for many in the industry.

It is not explicitly labelled as the top stock in its sector. However, Akums’ rapid growth and market presence reflect its importance in the pharmaceutical manufacturing landscape. The company’s focus on innovation and quality has enabled it to stay competitive in a rapidly evolving industry. As Akums continues to expand its reach, it remains dedicated to its mission of providing quality products and services.

How Akums is Revolutionising Contract Manufacturing in Pharma

Akums Drugs and Pharmaceuticals Ltd. is making major strides in the pharmaceutical industry. Founded in 2004 by the Jain brothers, Akums has grown to become India’s largest contract research and manufacturing services (CRAMS) company. This growth is driven by their commitment to quality and innovation.

Akums provides a range of services that cover the entire spectrum of pharmaceutical manufacturing. These services include formulation development, stability studies, regulatory approvals, packaging, and market launch. By offering such a broad array of services, Akums ensures that their clients can rely on them for all their manufacturing needs. This integrated approach simplifies the process for clients. It also ensures consistency and quality across all stages of production.

One of the key factors behind Akums’ success is its state-of-the-art manufacturing facilities. They operate over 15 advanced manufacturing units that are equipped with the latest technology. These facilities are capable of producing a wide range of dosage forms. This includes tablets, capsules, liquid orals, injectables, and more. The company’s commitment to maintaining high standards is evident in its numerous certifications, including WHO-GMP, ISO 9001, and ISO 14001.

Innovation is at the heart of Akums’ operations. The company invests heavily in research and development to stay ahead of industry trends. This focus on innovation has led to the development of new drug formulations and delivery systems. For instance, Akums recently received approval from the Drug Controller General of India (DCGI) to launch an antidiabetic drug called Lobeglitazone. This drug offers several advantages, including a higher safety profile. It also offers greater effectiveness at lower dosages.

Akums has also formed strategic partnerships with various companies. This is to expand their capabilities and market reach. In 2019, they received a significant investment from Quadria Capital, a healthcare-focused private equity firm. This partnership has enabled Akums to further enhance their manufacturing capabilities. It has also helped the company explore new growth opportunities. Additionally, Akums has collaborated with several multinational companies. This is to manufacture a diverse range of products, including pharmaceuticals, cosmetics, and more.

Sustainability is another area where Akums is making a difference. The company is committed to reducing its environmental footprint through various initiatives. These include the use of renewable energy sources and water conservation efforts. As a result, Akums contribute to environmental protection. It also ensures long-term operational efficiency and cost savings.

Looking ahead, Akums aims to continue its growth trajectory by expanding its market share and revenue. The company plans to increase its revenue to around ₹10,000 crore and capture a 20% market share in the next few years. To achieve these goals, Akums will focus on enhancing its service offerings and leveraging its partnerships. The company also plans to venture into new areas, such as biosimilars and vaccines, which present significant growth opportunities.

Overall, Akums Drugs and Pharmaceuticals Ltd. is revolutionising contract manufacturing in the pharmaceutical industry. The company achieves this through its comprehensive service offerings and quality. As the company continues to grow, it is well-positioned to meet the changing needs of the pharmaceutical industry. It is also ready to contribute to the development of safe and effective medications for patients worldwide.